CaRMA: Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study

Category:

Infectious Diseases

Eligibility Overview:

  • This is a non-therapeutic clinical trial that is only open to St. Jude patients.
  • Participant is receiving treatment for any disease at St. Jude.
  • Participant is age ≥ 5 years to < 25 years.
  • Participant has single or double lumen tunneled CVAD (ports not eligible).
  • Participant’s treating clinician does not plan to remove CVAD within 12 weeks.
  • Participant has not been previously enrolled in the CaRMA study or had past catheter resistance monitoring.

Description

Young people with cancer require intravenous (IV) treatment using long-term ‘central-lines’ for medication, and laboratory tests. Central-lines can develop blockages (occlusion) and cause infections or clots in blood vessels. If partial occlusion can be recognized, preventive treatment might prevent these complications.

To find out if weekly central-line resistance monitoring (CRM) can identify partial occlusion, 35 St. Jude patients will have weekly CRM for 12 weeks. CRM results in participants who develop occlusion, infection or clots will be compared with those who do not.

If the study finds that CRM is practical, further research could use this technique to try to prevent problems before they occur.

Objectives

  • To describe the feasibility of weekly CRM in children and adolescents treated at St. Jude.
  • To describe patient and caregiver adherence with weekly CRM in children and adolescents treated at St. Jude.
  • To explore the correlation between results of CRM and catheter occlusion or dysfunction.

Eligibility

  • Participant is receiving treatment for any disease at St. Jude.
  • Participant is age ≥ 5 years to < 25 years.
  • Participant has single or double lumen tunneled CVAD (ports not eligible).
  • Participant anticipates being present weekly at St. Jude for at least 12 weeks.
  • Participant’s treating clinician does not plan to remove CVAD within 12 weeks.
  • Participant does not have expected survival less than 12 weeks.
  • Participant has not been previously enrolled in the CaRMA study or had past catheter resistance monitoring.

Principal Investigator

Joshua Wolf, MBBS

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334
Email: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.